HIF1A and B-cell chronic lymphocytic leukemia: Concordantly, inhibition of HIF1α with the camptothecin derivative EZN-2208 exerts anti-tumor activities and acts as a chemosensitizer by interrupting protective microenvironmental interactions of CLL cells both in vitro and in vivo (108).